December 10, 2024 11:33 AM EST
Pharma

J&J, Leg­end’s Carvyk­ti clears a type of blood can­cer in ‘nine out of 10’ pa­tients

Ayisha Sharma

News Reporter

Lei Lei Wu

News Reporter

John­son & John­son and Leg­end Biotech say their CAR-T ther­a­py Carvyk­ti has the po­ten­tial to re­move all traces of dis­ease from cer­tain blood can­cer pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

Lil­ly fi­nances new $500M biotech fund man­aged by a16z

Four biotechs emerge with $800M and in-li­censed as­sets on Fri­day

Pfiz­er touts blad­der can­cer re­sults as first ad­vance­ment for some pa­tients 'in decades'

A service from the Financial Times